<code id='323019CD35'></code><style id='323019CD35'></style>
    • <acronym id='323019CD35'></acronym>
      <center id='323019CD35'><center id='323019CD35'><tfoot id='323019CD35'></tfoot></center><abbr id='323019CD35'><dir id='323019CD35'><tfoot id='323019CD35'></tfoot><noframes id='323019CD35'>

    • <optgroup id='323019CD35'><strike id='323019CD35'><sup id='323019CD35'></sup></strike><code id='323019CD35'></code></optgroup>
        1. <b id='323019CD35'><label id='323019CD35'><select id='323019CD35'><dt id='323019CD35'><span id='323019CD35'></span></dt></select></label></b><u id='323019CD35'></u>
          <i id='323019CD35'><strike id='323019CD35'><tt id='323019CD35'><pre id='323019CD35'></pre></tt></strike></i>

          Home / entertainment / fashion

          fashion


          fashion

          author:leisure time    Page View:725
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In